🔎 Trials Near Me

Pradžia › Astrocitoma › Pennsylvania

Astrocitoma klinikiniai tyrimai Pennsylvania

8 tyrimai dėl Astrocitoma ieško dalyvių vietose Pennsylvania.

Miestai Pennsylvania

Oficialus tyrimo tekstas (anglų kalba)

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • Christiana Care Health System-Concord Health Center, Chadds Ford
  • UPMC Hillman Cancer Center Erie, Erie
  • Forbes Hospital, Monroeville
  • ir dar 5
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07215910

Targeted Pediatric High-Grade Glioma Therapy

  • Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviaiStebimasis tyrimas
12 Months – 39 Years · Visoms lytims · Atnaujinta 2026-09-08 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • UPMC Hillman Cancer Center, Pittsburgh
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

  • Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai2 fazė
Amžius nuo 12 iki 39 · Visoms lytims · Atnaujinta 2026-09-01 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Thomas Jefferson University Hospital, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT05303519

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviaiAnkstyvoji 1 fazėLaukiami sveiki savanoriai
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2026-06-29 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai2 fazė
12 Months – 39 Years · Visoms lytims · Atnaujinta 2026-05-29 · NCT05843253

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

  • University of Pennsylvania, Philadelphia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-20 · NCT05345002

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.